Clinical Trials Logo

Filter by:
NCT ID: NCT05256303 Completed - Asthma Clinical Trials

Rural Hospital-Level Care at Home for Acutely Ill Adults

Start date: February 16, 2022
Phase: N/A
Study type: Interventional

This study examines the implications of providing hospital-level care in rural homes.

NCT ID: NCT05256108 Completed - Clinical trials for Human Abuse Potential

Assessment of Abuse Potential of Cebranopadol in Humans

Start date: March 28, 2022
Phase: Phase 1
Study type: Interventional

This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.

NCT ID: NCT05256095 Completed - Clinical trials for Autism Spectrum Disorder

Thinking in Speech for Children With Autism

Start date: May 12, 2021
Phase: N/A
Study type: Interventional

This study examines a cognitive therapy for autistic children, Thinking in Speech. Thinking in Speech helps children with autism independently cope with everyday events that cause stress, by developing their ability to use "inner speech".

NCT ID: NCT05256043 Completed - Diabetes Mellitus Clinical Trials

Investigation of Critically Ill Patients With Newly Diagnosed Diabetes

Start date: January 1, 2011
Phase:
Study type: Observational

The purpose of this study is to investigate the clinical outcomes and glucose control metrics of critically ill patients with previously undiagnosed diabetes compared to those with known diabetes at the time of admission to the intensive care unit (ICU).

NCT ID: NCT05255718 Completed - Inflammation Clinical Trials

Impact of Aronia Berry Consumption on Inflammation, Metabolites, and the Gut Microbiome

Start date: April 27, 2019
Phase: N/A
Study type: Interventional

The goal of this project is to elucidate interactions between the gut microbiome, anti-inflammatory/anti-oxidant food metabolomic signatures, and human inflammation phenotypes. Inflammation plays both direct and indirect roles in the development of type 2 diabetes (T2D), atherogenic cardiovascular diseases, and other causes of morbidity and mortality. Aronia melanocarpa (Aronia berries) are rich in bioactive polyphenolic compounds, which have been shown to lower inflammation and favorably impact metabolism. However, there is tremendous inter-individual variability in the bioavailability of polyphenolics and production of bioactive phenolic metabolites in the colon that depends, at least in part, on digestive metabolism by the gut microbiota. Little is known about the complex interactions among the gut microbiome, anti-inflammatory food metabolomic signatures, and human inflammation phenotypes. This study will utilize a systems-level approach to disentangle these complex interactions. The specific study objectives are as follows: 1. to determine the impact of Aronia supplementation on inflammation, metabolic health, and gut microbiome composition 2. to determine the static and dynamic metabolomic signature of Aronia based on an Aronia supplementation period and responses to a high-fat meal challenge

NCT ID: NCT05255445 Completed - Sickle Cell Disease Clinical Trials

Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

RBC-IMPACT
Start date: March 16, 2022
Phase:
Study type: Observational

Red Blood Cell - IMProving trAnsfusions for Chronically Transfused recipients (RBC-IMPACT) is an observational cohort study to assess donor, component, and recipient factors that contribute to RBC efficacy in chronically and episodically transfused patients. The objective of the study is to determine how specific genetic and non-genetic factors in donors and recipients may impact RBC survival after transfusion - in short, what factors on both the donor and recipient side may improve the efficacy of the transfusion.

NCT ID: NCT05255380 Completed - Stress Clinical Trials

Examine the Effects of Mindfulness in Woman With a History of Child Adversity

EMMA
Start date: June 3, 2022
Phase: N/A
Study type: Interventional

The aim of this pilot Randomized Controlled Trial (RCT) is to test whether brief mindfulness-based practices will improve well-being and health in women (age 30-50) with a history of early life adversity. Following a baseline visit (remotely via Zoom), participants are randomized (50% probability) to either a Mindful Activity group or a Mindful Awareness group. In the Mindful Activity group, participants will complete brief (approximately 5-10 min) audio-guided mindfulness practices twice a day (morning and evening) for 8 weeks using the study app. This is followed by a brief survey about their current thoughts and feelings. In the Mindful Awareness group, participants are asked to be mindful (pay attention) to their thoughts and feelings twice a day (morning and evening) for 8 weeks using the study app. After the 8-week intervention period, all participants complete a follow-up visit (remotely). Primary goals of the pilot RCT are to test acceptability, feasibility, and adherence.

NCT ID: NCT05255276 Completed - Healthy Adults Clinical Trials

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

Start date: February 2, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects.

NCT ID: NCT05255068 Completed - Clinical trials for Alzheimer's Disease and Related Dementias

OPTIMAL in NH Residents With Dementia

Start date: May 16, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to develop and refine OPTIMAL and evaluate its feasibility, fidelity, and usefulness. The OPTIMAL is designed to teach staff to effectively engage residents in eating using individualized, person-centered behavioral strategies.

NCT ID: NCT05254925 Completed - Phototoxic Response Clinical Trials

Phototoxicity Potential of 6% Bemotrizinol

Start date: February 28, 2022
Phase: Phase 2
Study type: Interventional

Phototoxicity Potential of Bemotrizinol (6%)